SONN · Sonnet Biotherapeutics Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $1.00M | - | - | $36.9K | $36.4K | $37.3K | $62.1K | $95.3K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $2.43M | $1.88M | $1.89M | $1.73M | $2.17M | $2.41M | $3.82M | $3.75M | $5.65M | $6.41M |
| SG&A | $1.38M | $2.34M | $1.96M | $1.80M | $1.70M | $1.54M | $1.88M | $1.90M | $2.28M | $1.90M |
| Total Operating Expenses | $3.81M | $4.23M | $3.85M | $3.53M | $3.87M | $3.95M | $5.70M | $5.65M | $7.93M | $6.04M |
| D&A | - | - | $3.2K | - | - | - | - | $3.2K | - | - |
| Operating Income | ($3.81M) | ($4.23M) | ($2.85M) | ($3.53M) | ($3.87M) | ($3.92M) | ($5.66M) | ($5.61M) | ($7.87M) | ($8.21M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | $158.4K | - | - | - | - | - | - | - |
| Net Income | ($3.78M) | ($3.49M) | ($3.16M) | ($3.51M) | $365.4K | ($3.95M) | ($5.67M) | ($5.54M) | ($7.88M) | ($8.21M) |
| EPS - Basic | ($0.95) | ($0.89) | ($1.56) | ($0.70) | $0.08 | ($0.13) | ($0.34) | ($1.44) | ($0.27) | ($0.14) |
| EPS - Diluted | ($0.95) | ($0.89) | ($1.56) | ($0.70) | $0.07 | ($0.13) | - | - | - | - |
Balance Sheet
| Line item | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.12M | $2.06M | $149.5K | $149.5K | $3.79M | $2.27M | $11.39M | $1.70M | $3.05M | $13.64M |
| Accounts Receivable | - | $500.0K | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.94M | $1.75M | $1.64M | $2.18M | $1.75M | $2.20M | $4.50M | $4.57M | $4.75M | $4.04M |
| Current Assets | $14.34M | $3.26M | $6.73M | $2.12M | $5.22M | $4.74M | $13.05M | $4.60M | $5.41M | $14.92M |
| Total Assets | $14.88M | $3.84M | $7.18M | $2.77M | $5.91M | $5.43M | $13.31M | $4.94M | $5.83M | $15.05M |
| Current Liabilities | $4.10M | $3.17M | $3.12M | $3.21M | $2.76M | $5.52M | $7.77M | $8.29M | $8.16M | $6.51M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $4.10M | $3.17M | $3.15M | $3.26M | $2.86M | $5.66M | $7.94M | $8.48M | $8.37M | $6.51M |
| Stockholders' Equity | $10.79M | $662.3K | $4.04M | ($485.7K) | $3.05M | ($226.0K) | $5.37M | ($3.54M) | ($2.54M) | $8.53M |
| Retained Earnings | ($133.69M) | ($124.33M) | ($120.84M) | ($117.68M) | ($111.05M) | ($110.24M) | ($102.62M) | ($96.95M) | ($91.41M) | ($76.10M) |
Cash Flow
| Line item | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($2.91M) | - | - | - | - | ($5.92M) | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | $7.62M | - | - | - | - | $4.56M | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | -284.9% | - | - | -10625.0% | -15543.3% | -15064.8% | -12674.6% | -8613.3% |
| EBITDA margin | - | - | -284.6% | - | - | - | - | -15056.2% | - | - |
| Net margin | - | - | -316.1% | - | - | -10710.3% | -15549.7% | -14876.2% | -12690.3% | -8611.5% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | 188.6% | - | - | 6538.6% | 10472.3% | 10054.9% | 9100.8% | 6719.8% |
| SG&A / Revenue | - | - | 196.3% | - | - | 4186.4% | 5171.0% | 5109.9% | 3673.8% | 1993.6% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -25.4% | -91.0% | -44.0% | -126.5% | 6.2% | -72.7% | -42.6% | -112.1% | -135.1% | -54.6% |
| Return on equity | -35.0% | -527.2% | -78.3% | 721.7% | 12.0% | 1746.5% | -105.6% | 156.7% | 310.3% | -96.2% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.50 | 1.03 | 2.15 | 0.66 | 1.89 | 0.86 | 1.68 | 0.55 | 0.66 | 2.29 |
| Quick ratio | 3.50 | 1.03 | 2.15 | 0.66 | 1.89 | 0.86 | 1.68 | 0.55 | 0.66 | 2.29 |
| Cash ratio | 1.25 | 0.65 | 0.05 | 0.05 | 1.37 | 0.41 | 1.47 | 0.21 | 0.37 | 2.09 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.38 | 5.79 | 1.78 | -5.70 | 1.93 | -24.03 | 2.48 | -1.40 | -2.30 | 1.76 |
| Liabilities / Assets | 0.28 | 0.83 | 0.44 | 1.18 | 0.48 | 1.04 | 0.60 | 1.72 | 1.44 | 0.43 |
| Efficiency | ||||||||||
| Asset turnover | - | - | 0.14 | - | - | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | 2584.2% | - | - | -40.6% | -61.8% | -71.3% | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | -81.3% | -81.4% | -79.3% |
| Revenue CAGR (5y) | - | - | -37.2% | - | - | -67.5% | -67.9% | -67.3% | -64.3% | -61.1% |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -7.9% | -9.3% | 49.2% | 9.9% | 31.7% | 50.2% | 31.0% | 9.7% | -26.1% | -36.0% |
| Net income growth (YoY) | -7.7% | - | 43.0% | 11.2% | - | 49.9% | 31.0% | 10.6% | -28.8% | -35.9% |
| EPS growth (YoY) | -35.7% | - | - | -438.5% | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | -78.3% | - | -114.9% | -43.1% | 91.1% | -37.1% | - | - | 322.0% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Sonnet BioTherapeutics Holdings against the 5 most active filers in the same SIC group.